Skip to Content
Global News Select

Glympse Bio Raises $46.7 Million in Series B Funding Round

By Colin Kellaher

Biotechnology startup Glympse Bio Wednesday said it raised $46.7 million in an oversubscribed Series B financing at an undisclosed valuation.

Glympse said Bill Maris' Section 32 venture-capital firm led the round, which also included participation from new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures and Catalio Capital Management, along with existing investors LS Polaris Innovation Fund, ARCH Venture Partners, CRV, GreatPoint Ventures and Gilead Sciences Inc.

The Cambridge, Mass., company founded in 2015 has now raised $75.3 million.

Glympse said it will use the new funding to support continued development of its novel biosensor platform in non-alcoholic steatohepatitis, a chronic liver condition commonly known as NASH, and to explore the potential of the platform across multiple other areas, such as oncology and infectious diseases.

Gilead last year announced a deal to use Glympse's biomarker technology in its NASH clinical programs.

Write to Colin Kellaher at

(END) Dow Jones Newswires

July 15, 2020 12:15 ET (16:15 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.